Two cold-recombinant influenza A (HI N 1) viruses were tested in several groups of human volunteers. Only minor clinical symptoms were seen and no febrile reactions occurred. With serologically primed individuals virus shedding was low, but a high proportion showed rises in serum antibody levels after vaccination and mean titres were high. With serologically unprimed volunteers shedding was high, about 75% yielding viruses but only at low titres and for a short duration. No revertant viruses were found and there was no evidence of transmission t o potentially susceptible individuals housed in close contact to the vaccinees.
(H3N2) influenza drift period. All volunteer studies, therefore, would have been made with persons who were likely to have had previous infection with H3N2 viruses. Thus, even volunteers without detectable antibody to the A/Victoria/3/75 (H3N2) virus are likely to have been primed immunologically to H3N2 subtype viruses. Priming might have mediated the clinical response to live-virus vaccination, for example, by ameliorating residual virulence of an apparently attenuated strain. The serological responses seen might also have resulted from an amnestic response to previously encountered antigens. It was of great interest, therefore, to study the clinical and immunological responses to H l N l virus recombinants. As strains of this subtype had not been epidemic since 1956, a substantial population of young adults existed with no previous exposure to such viruses. They would, therefore, be immunologically unprotected. Indeed, substantial outbreaks of influenza were reported in children and young adults between and 1979 [Zhadnov et al, 1978 Gregg et al, 19781 . We describe here the clinical, virological, and serological responses found in both primed and unprimed volunteers to two H l N l cold-recombinant influenza viruses. We also show from subsequent challenge infections that such live-virus vaccination induces substantial protection for up to at least five months.
MATERIALS AND METHODS

Viruses
The origin and properties of the two viruses, recombinant CR33 and recombinant BG12, will be described [Reeve et al, unpublished information] . The CR33 recombinant was derived by Professor Maassab in his laboratory in Michigan, by recombination between the A/AA/6/60 (H2N2) cold-adapted virus and the A/USSR/90/77 (HlNl) virus. This work was supported by the US government NAIAD contract No. 1-A1-72521. Subsequent preclinical and clinical studies with CR33 were performed at the Sandoz Research Institute, Vienna. The other recombinant, BG12, was derived in our laboratories by recombination between the A/AA/6/60 (H2N2) cold-adapted virus and the A/USSR/92/77 (HlN1) virus. The genes coding for HA, NA, and one of the P proteins of virus BG12 are derived from the wild-type virus. In the case of the CR33, only the genes coding for the surface antigens haemagglutinin (HA) and neuraminidase (NA) derive from the wild-type virus.
Volunteers
Volunteers for two studies were recruited from seronegative male or female university students aged 19 to 26 years who had given informed consent. Seronegative subjects were selected where serum haemagglutination inhibition (111) and serum neuraniinidase inhibition (NI) titres were < 1:8 using an A/USSR/92/77 (HlN1) antigen. Pregnancy, current or recent upper respiratory tract infections, and known sensitivity t o egg proteins were grounds for exclusion of volunteers from the study, The volunteers were given the following medical and clinical laboratory exaniinations before admission to the studies and excluded if abnormalities were detected: complete blood counts, chest X ray, blood chemistry (BUN, SGOT, SGPT, alkaline phosphatase, bilirubin, and fasting glucose levels), patellar tendon reflexes, and urinalysis. They were lodged at a sequestered wing of an hotel in the Vienna Woods in double and single rooms and so separated from the public. Serum samples collected immediately before vaccination and three weeks there. after, were assayed for HI or NI using techniques described [Kunz et al, 19771 and an A/USSR/92/77 (HlN1) antigen. SN antibodies were assayed using a plaque reduction assay and virus A/USSR/92/77 (HINl).
Challenge Studies
Volunteers from the previous trials with young volunteers were asked to take part in a further trial in which their resistance to infection with the recombinant BG12 was tested. Challenge studies were made four months and five months, respectively, after the original vaccination studies. An additional age-matched unimmunised group was also included. A total of 52 volunteers were included in this study. All volunteers received 6.4 (log,,) EIDso while the volunteer remained prone, head tilted back, for approximately one minute. Subsequently, every day for four days nasal swabs were obtained for virusisolation studies. Three weeks after the start of the challenge trial a further serum sample was taken for antibody determinations. minimal essential medium (MEM) containing 10% (v/v) tryptose phosphate broth as transport medium. On the same day of collection, swab material was inoculated into Madin Derby Canine Kidney (MDCK) cell cultures in the presence of MEM with 10 pgrn/ml trypsin for virus isolation [Oxford et al, 19791. Virus isolations were made from material collected by nasal swabs using Eagle's
RESULTS
Trials in Young Seronegative Adult Volunteers
In both trials volunteers were inoculated intranasally with either recombinant CR33, recombinant BG12, or physiological saline. Inoculations were given in 0.4-ml volumes according to a computer-generated randomisation list.
In the second trial a hglier dosage was given and volunteers received either 8.6 (loglo) EIDSO, recombinant BG12 or 8.7 (loglo) ED5* recombinant CR33, or placebo.
Clinical Reactions After Vaccination
All reactions to vaccine or placebo were mild ( Table I) . The most frequently observed reactions to live-virus vaccine were slight "stuffy nose" or "running nose." With the first study five of 12 volunteers given recombinant CR33 and three of 12 given reIn the first trial, volunteers received 7.4 (log, , ) EID, of virus vaccine or placebo. *Fever was regarded as an oral temperature of 38OC or higher. Systemic reactions, headache, fatigue, muscular pains or weakness, were included when recorded as "moderate" on any one occasion or "slight" on at least two consecutive days. No "severe" reactions were seen. Upper respiratory tract reactions, cough, sore throat, stuffy or running nose are included using the same criteria.
combinant BG12 reported stuffy or running noses. One volunteer given recombinant CR33 reported a running nose, slight cough, and headache and one a stuffy nose and myalgia. A further volunteer given recombinant CR33 complained of headache and a running nose on the day of inoculation. With recombinant BG12 two volunteers with running noses complained of slight or moderate headaches. In this study five of 12 volunteers given placebo also complained of slight running or stuffy noses, two had coughs, and one a moderate headache. In our second study with young volunteers a similar picture was seen. With recombinant CR22 three of seven had running or stuffy noses; with recombinant BG12 three of eight had running or stuffy noses and two in addition complained o f slight sore throats. In this study no reactions were observed from the placebo group (Table I) .
Two volunteers who had received recombinant BG12 showed transitory rises in body temperature on the second day after inoculation. The maximum recorded temperature being 38.9"C with one volunteer and 38.0"C with the other. All other volunteers recorded normal body temperatures.
( Table 11) . No viruses were isolated from the placebo groups, and no revertant viruses were found. It was evident from the virus isolations that most volunteers were infected with the live-recombinant viruses.
The serum antibody responses were low. Only a proportion of the volunteers showed increases in serum titres whether measured in the HI, NI, or SN tests. Increasing the dose inoculated did not markedly increase the number of volunteers showing seroconversion (Table 11 ). The overall percentage of volunteers showing increases in serum titres was approximately 50% and the mean serum HI titre was 1 : 12 (Table 11) .
A high proportion of volunteers shed viruses for up to seven days after inoculation
Effect of Second Vaccination
prompted us to reinoculate the volunteers with one of several preparations. Firstly, we considered whether the low titres found were merely a response to the antigenic mass of The finding of low rates of seroconversion and low mean serum antibody titres the locally applied virus. Accordingly, a group of volunteers previously inoculated with placebo material and a further group who had received live-recombinant BG 12 were reinoculated by the intranasal route with a formalin-inactivated preparation of the recombinant BG12. None of the volunteers from either group showed a change in serum antibody titres, Table 111 . From this we concluded that the responses found were not due merely to the antigenic mass of the live-virus preparations. This experiment also showed that no booster type of response could be elicitated using killed vaccine intranasally. Volunteers from the group which had received recombinant CR33 were revaccinated with the subunit vaccine Sandovac@ [Bachmayer et al, 1976; Kunz et al, 19771 containing 10 pg A/USSR/90/77 (HlNl) per dose. After the booster immunization with SandovacO one half (55%) of the volunteers showed rises in serum HI titres and the GMT was 1:20, Table 111 . This response was not significantly higher than the response of unprimed individuals to a single dose of the subunit vaccine. In another attempt to boost antibody responses, all of the volunteers from study No. 2 were inoculated intranasally with 8.1 (log,,) EID,, recombinant BG12. The changes in serum titres observed did not differ from the immune response observed after the first dose of the vaccine (Table 111) .
Trial in Volunteers "Primed" Against H l N l Influenza
To test the response to live vaccination with H l N l influenza A viruses in primed individuals, eight volunteers over 30 years old were inoculated intranasally with 8.1 (log, o) EID, of the recombinant BG12.
Four of the volunteers possessed initial titres of 1 :8 or less: All showed twofold or greater rises in serum HI titres 38 days after vaccination. The mean titres were 1 :22. The remaining four volunteers possessed initial titres of 1 : 16 or more. None showed significant rises in serum HI titres (Table IV) .
Challenge Trial
From the control group of 11 unimmunised volunteers, seven shed viruses up to four days aftcr infection. The maximum titre found was 4.0 (logl ,) TCID, and the mean was 2.5 (log, o) TCID, (Table V) . vaccines administered intranasally. Only Sandovac given IM/SC. *Volunteers from previous studies (Table I) were reimmunised with the preparation indicated.
Volunteers in study No. 2 received 8.1 (loglo) EID,, recombinant BG12 as a booster inoculation. Serum haemagglutination inhibition (HI) responses were measured using homologous antigens three weeks after booster inoculation. volunteer shed virus on the fourth day after infection only.
*Volunteers from previous vaccine studies and an invaccinated control group were given 6.8 (loglo) EID,,, intranasally.
Virus isolations were made in MDCK cells up to four days after infection. n X A similar shedding pattern was found with the ten volunteers given placebo in a first trial made five months before the challenge study. Six of the ten shed viruses for as long as four days. The maximum titre was 4.0 (log, o ) TCIDS , , and the mean was 2.2 (log,,) TCLD, , , ( Table V) . The overall infection rate of both "unprotected" groups was 64%.
From the volunteers previously vaccinated with recombinant BGl2, CR33, or both viruses, only three virus isolations were obtained from a total number of 30 volunteers (Table V) . Thus, previous vaccination with live-virus vaccine induced a highly significant degree of protection in comparison with the control groups @ < 0.001). The numbers of volunteers in each group was small and so it is not possible to compare the efficacy of the different vaccination schedules used. But there was no major difference between volunteers immunized four months or five months before challenge. The viruses reisolated proved antigenically identical to A/USSR/92/77 (HlN1) in HI tests.
DISCUSSION
When young double-seronegative and "unprimed" volunteers were infected with cold-recombinant influenza A viruses of the subtype HlN1, a high proportion were infected as judged from virus shedding. Despite prolonged virus shedding, serum antibody responses were poor. Only a proportion showed changes in serum HI or SN titres and mean titres were low. We concluded that the serological response which we could detect was due to infection since intranasal administration of homologous-killed antigen to unimmunised volunteers did not induce any immune response at all. We could not boost the immune response to H l N l viruses after vaccination with live, attenuated viruses by killed-virus antigen applied intranasally or by subsequent intranasal inoculation with live, attenuated virus.
The poor immune response was not due, however, to a defect in the antigenicity of the recombinants. Both induced, high titres of circulatory antibody in hamsters infected intranasally [Reeve et al, unpublished information] . Additionally, good immune responses were seen in the volunteers from the higher age group where the response was similar to that found with a cold-recombinant H3N2 influenza virus [Moritz et al, 19781 .
The serum antibody levels found in the younger volunteers would give no evidence of protection against infection with homologous virus. Hobson [Hobson et al, 19721 from a challenge study of volunteers previously immunized with a killed-influenza (H3N2) vaccine estimated the 50% protective antibody level to be 1 :36. In our studies with live H l N l influenza virus vaccines in unprimed persons, such serum HI titres were not achieved even after booster vaccinations. We could not, therefore, conclude from serological results that vaccination of unprimed persons with the live H l N l vaccines would confer protection against reinfection. A challenge study, however, using live attenuated virus subsequently demonstrated a highly significant degree of protection four and five months after vaccination.
